Ester derivatives of nucleoside inhibitors of reverse transcriptase: II. Molecular systems for combined therapy with 3'-azido-3'-deoxythymidine and 2',3'-didehydro-3'-deoxythymidine
Berezovskaia, I.V.; Chudinov, M.V.
Bioorganicheskaia Khimiia 31(5): 451-465
2005
ISSN/ISBN: 0132-3423 PMID: 16245688 Document Number: 591265
The methods of synthesis of conjugates of anti-HIV nucleosides with various compounds, such as protease inhibitors, peptides, polysaccharides, and bicyclames, are considered; they are designated for the combined therapy of HIV.
Document emailed within 1 workday
Related Documents
Berezovskaia, I.V.; Chudinov, M.V. 2005: Ester derivatives of nucleoside inhibitors of reverse transcriptase: I. Molecular transport systems for 3'-azido-3'-deoxythymidine and 2',3'-didehydro-3'-deoxythymidine Bioorganicheskaia Khimiia 31(4): 339-356Engchanil, C.; Kosalaraksa, P.; Lulitanond, V.; Lumbiganon, P.; Chantratita, W. 2006: Multi-drug resistant HIV-1 reverse transcriptase genotype in children treated with dual nucleoside reverse transcriptase inhibitors (NRTIs) Journal of the Medical Association of Thailand 89(10): 1713-1720
2000: Non-nucleoside reverse transcriptase inhibitors. First line therapy MMW Fortschritte der Medizin 142(3 Suppl): 34-35
Ahluwalia, G.S.; Gao, W.Y.; Mitsuya, H.; Johns, D.G. 1996: 2',3'-Didehydro-3'-deoxythymidine: regulation of its metabolic activation by modulators of thymidine-5'-triphosphate biosynthesis Molecular Pharmacology 50(1): 160-165
Nicolas, F.; De Sousa, G.; Thomas, P.; Placidi, M.; Lorenzon, G.; Rahmani, R. 1995: Comparative metabolism of 3'-azido-3'-deoxythymidine in cultured hepatocytes from rats, dogs, monkeys, and humans Drug Metabolism and Disposition: the Biological Fate of Chemicals 23(3): 308-313
Chow, H.H.; Li, P.; Brookshier, G.; Tang, Y. 1997: In vivo tissue disposition of 3'-azido-3'-deoxythymidine and its anabolites in control and retrovirus-infected mice Drug Metabolism and Disposition: the Biological Fate of Chemicals 25(4): 412-422
Mankhatitham, W.; Luaengniyomkul, A.; Manosuthi, W. 2012: Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy Journal of the Medical Association of Thailand 95(2): 163-169
Ruţă, S.M.; Cernescu, C. 1994: Syncytium forming capacity of HIV 1 strains in inhibited by pretreatment of CD4 expressing cells with 3'-azido-3'-deoxythymidine but not by alpha interferon Revue Roumaine de Virologie 45(3-4): 171-183
Brzezińska, E.; Glinka, R. 2002: Search for new non-nucleoside inhibitors of HIV-1 reverse transcriptase (HIV-1 RT) Acta Poloniae Pharmaceutica 59(5): 379-386
Russo, G.; Paganotti, G.M.; Soeria-Atmadja, S.; Haverkamp, M.; Ramogola-Masire, D.; Vullo, V.; Gustafsson, L.L. 2016: Pharmacogenetics of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource-limited settings: Influence on antiretroviral therapy response and concomitant anti-tubercular, antimalarial and contraceptive treatments Infection Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases 37: 192-207
Wainberg, M.A.; Sawyer, J.P.C.; Montaner, J.S.G.; Murphy, R.L.; Kuritzkes, D.R.; Raffi, F. 2005: Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection Antiviral Therapy 10(1): 13-28
Tarby, C.M. 2004: Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors Current Topics in Medicinal Chemistry 4(10): 1045-1057
Stankov, M.V.; Lücke, T.; Das, A.M.; Schmidt, R.E.; Behrens, G.M.N. 2007: Relationship of mitochondrial DNA depletion and respiratory chain activity in preadipocytes treated with nucleoside reverse transcriptase inhibitors Antiviral Therapy 12(2): 205-216
Flandre, P.; Descamps, D.; Joly, V.; Meiffrédy, V.; Tamalet, C.; Izopet, J.; Aboulker, J-Pierre.; Brun-Vézinet, Fçoise. 2003: Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received Antiviral Therapy 8(1): 65-72
Vemula, S.; Kerr, S.; Pancharoen, C.; Siripong, A.; Kosalaraksa, P.; Engchanil, C.; Chuamchaitrakool, A.; Intasan, J.; Lumbiganond, P.; Phanuphak, P.; Ananworanich, J. 2007: Incidence and risk factors for non-nucleoside reverse transcriptase inhibitors (NNRTI)-related rash in Thai children with HIV infection Journal of the Medical Association of Thailand 90(11): 2437-2441
Sachdeva, R.K.; Wanchu, A.; Bagga, R.; Malla, N.; Sharma, M. 2010: Effect of non-nucleoside reverse transcriptase inhibitors on cytokine, chemokine, and immunoglobulin profiles in serum and genital secretions of HIV-infected women Journal of Interferon and Cytokine Research: the Official Journal of the International Society for Interferon and Cytokine Research 30(5): 299-310
Ramachandran, G.; Kumar, A.K.Hemanth.; Ponnuraja, C.; Ramesh, K.; Rajesh, L.; Chandrasekharan, C.; Swaminathan, S. 2013: Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients Indian Journal of Medical Research 138(6): 955-961
Arenas-Pinto, A.; Bhaskaran, K.; Dunn, D.; Weller, I.V.D. 2008: The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial Antiviral Therapy 13(2): 289-295
Balzarini, J.; De Clercq, E. 1987: Differential affinities of pyrimidine nucleoside analogues for deoxythymidine and deoxycytidine kinase determine their incorporation into murine leukemia L1210 cells Acta Biochimica Polonica 34(2): 63-77
Song, L.; Ding, S.; Ge, Z.; Zhu, X.; Qiu, C.; Wang, Y.; Lai, E.; Yang, W.; Sun, Y.; Chow, S.A.; Yu, L. 2018: Nucleoside/nucleotide reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signalling in endothelial cells British Journal of Pharmacology 175(8): 1241-1259